The Inhibitive Effect of sh-HIF1A-AS2 on the Proliferation, Invasion, and Pathological Damage of Breast Cancer via Targeting miR-548c-3p Through Regulating HIF-1 α /VEGF Pathway in vitro and vivo [Retraction]

Guo X, Lee S, Cao P. *Onco Targets Ther.* 2019;12:825—834.

- Figure 4A panel sh-HIF1A-AS2+inhibitor appears to be duplicated with Figure 5D sh-HIF1A-AS2+HIF-1 α .

The Editor and Publisher of *OncoTargets and Therapy* wish to retract the published article.

The authors could not provide the satisfactory raw data for the study and the Editor has determined the findings are no longer valid and requested for the paper to be retracted.

The journal was notified of potential image duplication between Figures 4A and 5D:

- Figure 4A panel Ctrl appears to be duplicated with Figure 5D Ctrl.
- Figure 4A panel sh-HIF1A-AS2 appears to be duplicated with Figure 5D panel sh-HIF1A-AS2.
- Figure 4A panel miR-548c inhibitor appears to be duplicated with Figure 5D panel CMV-HIF-1 α .

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>